Biotech VC Funds

Better Ventures is a mission-driven VC firm investing in early-stage startups that harness cutting-edge technology to address pressing global challenges. Their notable investments include Meati, a sustainable protein innovator, and SMBX, a platform democratizing business financing. With a focus on sectors like climate tech, human health, and equitable economies, they back diverse teams aligned with the UN's Sustainable Development Goals. Based in Oakland, Better Ventures leads seed rounds, providing active support for founders committed to making a measurable impact. The team looks for companies that can scale profitably while driving social and environmental change, ensuring purpose and profit go hand-in-hand. Better Ventures prefers founders who blend technological innovation with a clear mission. They typically write checks of $500k to $1 million and often lead or co-lead rounds. The firm emphasizes strong partnerships, working closely with founders to scale their impact. Startups should approach Better Ventures with a well-defined purpose, as they prioritize purpose-driven innovation. The founding team includes Rick Moss and Jenny Kassan, both seasoned in impact investing and business development. Better Ventures' geographic focus spans the U.S., especially targeting hubs of innovation. Their approach to funding emphasizes scalability, sustainability, and measurable impact, creating value for both investors and society.

Beyond Next Ventures, founded in 2014 and based in Tokyo, focuses on early-stage investments in deep tech startups, primarily in Japan and India. The firm invests in various sectors including medtech, healthcare, biotechnology, agriculture, food, digital, space, and climate technology​. Notable investments include companies like MediBuddy, GigIndia, QD Laser, and Susmed. MediBuddy is a significant player in telemedicine and healthcare services in India, while QD Laser and Susmed are notable for their IPOs on the Tokyo Stock Exchange​. Beyond Next Ventures typically leads early-stage financing rounds, offering extensive support through their incubator programs aimed at commercializing advanced research. The firm has about $340 million under management, underscoring its commitment to fostering innovation in deep tech and science-based startups​. The leadership team, including CEO Tsuyoshi Ito and Managing Director Kengo Ueha, brings a wealth of experience and strategic insight, supporting startups through growth management, market entry, and expansion strategies.

Bharat Fund, also known as Bharat Innovation Fund, is a venture capital firm based in India that focuses on early-stage investments in deep-tech and IP-driven startups. Founded under the aegis of CIIE.CO at IIM Ahmedabad, the fund aims to support companies that provide innovative solutions in sectors such as healthcare, agriculture, renewable energy, and advanced technology. The fund typically invests in pre-Series A and Series A stages, providing not just capital but also strategic insights, market development support, and access to extensive networks to help startups scale effectively. Bharat Fund’s mission is to back transformative entrepreneurs who are addressing some of the toughest global challenges, with the goal of turning their ventures into globally competitive and disruptive companies. Bharat Fund’s portfolio includes startups that are leveraging technology to create significant impact. By remaining deeply engaged throughout the lifecycle of their investments, Bharat Fund aims to significantly de-risk the conversion of innovative ideas into successful companies. The fund’s name, "Bharat," is inspired by the traditional name for India and reflects their dedication to fostering breakthrough innovations from the country. Their approach combines a decade of early-stage investing experience with support from key partners like Tata Trusts, enabling them to build a robust platform for nurturing high-potential startups.

Big Idea Ventures, founded in 2018, is a leading venture capital firm focusing on the alternative protein and food technology sectors. With over 110 early-stage investments, they have become the most active investor in FoodTech globally. The firm operates through its New Protein Fund and Generation Food Rural Partners fund, supporting innovative companies in plant-based, cell-based, and fermentation-enabled food technologies. Notable investments include companies like Naturannova, which creates sustainable peptide-based flavors using AI, and SoundEats, a cultivated seafood pioneer. Other standout portfolio companies are New Wave Biotech, which develops bioprocess optimization software, and Loki Foods, which produces plant-based seafood using renewable energy in Iceland. Big Idea Ventures runs bi-annual accelerator programs in New York, Paris, and Singapore, providing selected companies with a $200,000 investment and access to an extensive network of partners and investors. This hands-on support helps startups navigate product development, scaling, and market entry. Led by founder Andrew D. Ive, Big Idea Ventures collaborates with strategic partners like Temasek Holdings, Tyson Ventures, and Givaudan, aiming to drive significant advancements in food security and sustainability.

Big Pi Ventures is a venture capital firm based in Greece, focusing on seed and early-stage investments, particularly in deep-tech and science-driven startups. Established with a vision to drive transformative innovation, Big Pi partners with exceptional teams developing technologies that address significant global challenges. Their investments span various sectors, including artificial intelligence, health and life sciences, and climate technology, often targeting companies with strong intellectual property or technological advantages. The firm is anchored in Greece but maintains a global perspective, requiring that its portfolio companies establish substantial operations in Greece. Notable investments include companies like TileDB, Orfium, and Navenio, reflecting their commitment to backing ventures that have the potential to scale internationally. Big Pi is led by a team of seasoned entrepreneurs and investors, including Marco Veremis, co-founder of Upstream, and Alex Eleftheriadis, a pioneer in video compression technology. The team offers more than just capital, providing strategic support in areas like product design, scaling, and global market expansion. Their latest rebranding and new fund, announced in 2023, signify their ongoing commitment to fostering innovation and supporting the next generation of tech leaders.

Binance Labs, the venture capital arm and accelerator of Binance, focuses on empowering the decentralized web through strategic investments in blockchain startups. Founded in 2018, Binance Labs has supported over 200 projects across more than 25 countries, with a portfolio that includes prominent names like Polygon, Perpetual Protocol, and Dune Analytics. The firm invests in early-stage companies that demonstrate strong product innovation, sustainable business models, significant traction, and robust technology. Their strategic approach includes equity stakes and token deals, emphasizing security, compliance, user conversion, and enhancing user experience across various regions. Geographically, Binance Labs has a global reach but places a significant focus on expanding blockchain infrastructure and Web3 applications. Recent investments include a substantial stake in Aptos Labs, aimed at developing a high-performance, production-ready layer-1 blockchain. Leading the venture is Yi He, Co-Founder of Binance, who oversees a $9 billion asset portfolio. Binance Labs supports founders through their Incubation Program, providing advisory services, operational support, and a strong network to help projects navigate the complex blockchain landscape. For startups interested in joining Binance Labs, they should demonstrate clear innovation, a viable business model, and a commitment to long-term growth in the blockchain ecosystem.

BioAdvance is a prominent life sciences venture capital fund based in the mid-Atlantic region, focusing on therapeutics, diagnostics, medical devices, research tools, and health IT. With over 100 investments, they have achieved 23 exits and brought 12 FDA-approved products to market. Their portfolio companies, such as Palvella Therapeutics and Strados Labs, have attracted significant follow-on funding, collectively raising over $4.2 billion. BioAdvance operates as an evergreen fund, enabling continuous reinvestment and long-term partnership with entrepreneurs. The fund emphasizes capital efficiency and works closely with startups to maximize limited resources. Their investment strategy centers on advancing human health technologies with potential for high impact, targeting early-stage companies with scalable innovations. Led by a team of seasoned executives, scientists, and physicians, BioAdvance is collaborative, often playing an active role in company growth and guiding entrepreneurs toward successful exits via IPOs or acquisitions. They prefer to engage with startups that have a strong business case and well-developed pitch, ensuring a strong fit with their mission of improving human health.

Bioeconomy Capital is a San Francisco and Seattle-based venture capital firm founded in 2015. The firm focuses on early-stage investments in biotechnology, life sciences, and sustainability technology. Bioeconomy Capital is driven by the goal of accelerating the biotechnology revolution by supporting companies that are developing critical infrastructure and innovative technologies for the 21st century. With a strong foundation in synthetic biology, Bioeconomy Capital leverages decades of expertise in life sciences and engineering to back startups with transformative potential. The firm’s portfolio includes notable companies such as Zymergen, Riffyn, Synthace, RoosterBio, and Arzeda. Bioeconomy Capital typically invests between $100K and $5M, with a sweet spot of $1.5M per investment. The firm has a global focus, primarily investing in the U.S. but occasionally supporting companies in the U.K. and other regions. Led by managing directors Rob Carlson and Rik Wehbring, Bioeconomy Capital plays a strategic role in helping its portfolio companies navigate the complexities of scaling biotech and sustainability solutions​.

BioGeneration Ventures (BGV) is a prominent venture capital firm based in Naarden, Netherlands, specializing in early-stage European biotech companies. With over €400 million under management, BGV focuses on sectors like biopharma, medtech, and diagnostics. Their portfolio features notable investments in companies such as AcertaPharma, argenx, and New Amsterdam Pharma, underscoring their success in advancing groundbreaking scientific innovations and addressing unmet medical needs. BGV typically engages in seed to early growth stages, strategically guiding companies through clinical trials and drug development to achieve substantial exits. Their rigorous selection process ensures they back ventures with the highest potential for impactful outcomes. BGV's investment philosophy centers on combining deep scientific expertise with commercial insight to build world-class biotech firms. The firm is led by a team of experienced professionals, including managing partners Edward van Wezel and Suzanne Morsink, who bring extensive backgrounds in life sciences and venture capital. They actively support portfolio companies with strategic guidance, leveraging their broad network and industry knowledge to drive growth and innovation. BGV is committed to fostering the next generation of biotech leaders, with a clear focus on creating value for both investors and society by addressing critical health challenges through cutting-edge science and technology

BioMedPartners, through its BioMedInvest funds, focuses on venture capital investments in early to mid-stage companies in the biotechnology, pharmaceutical, and medical technology sectors. Based in Basel, Switzerland, the firm supports innovations primarily in the Alpine region and other European markets. Notable portfolio companies include Aleva Neurotherapeutics, developing next-generation implants for deep brain stimulation; Anergis, which focuses on peptide-based immunotherapies for allergies; and Evolva, a biotech firm creating sustainable ingredients for health and nutrition. Additionally, BioMedPartners has invested in companies like Hookipa Biotech, which develops novel immunotherapies for infectious diseases and cancer, and Sequana Medical, specializing in implantable fluid management systems. The BioMedPartners team is led by General Partners such as Dr. Markus Hosang and Dr. Michael Wacker, who bring extensive experience in drug development, finance, and technology. The firm takes an active role in the development of its portfolio companies, often leading investment rounds and participating as a syndicate partner​.

Bioqube Ventures is a specialist life sciences venture capital firm focused on early-stage investments in Europe, particularly in therapeutic assets and disruptive healthcare technologies. Founded in 2016 by Debora Dumont and Nico Vandervelpen, the firm launched its independent fund, Bioqube Factory Fund I, in 2020. This fund, which has secured over €60 million in its initial closing, aims to support the development of breakthrough therapies by leveraging Bioqube's unique dual investment model. This model includes both traditional venture investments and a "Create" strategy, which focuses on de-risking projects before establishing new ventures. The fund's strategy is deeply rooted in supporting high-potential scientific innovations, transforming them into commercially viable biotechnologies. Bioqube has strong partnerships with prominent investors like the European Investment Fund, Johnson & Johnson Innovation, and Genmab, further bolstering its ability to drive significant advancements in the life sciences sector. The Bioqube team is composed of experienced fund managers, sector experts, and serial entrepreneurs, bringing a hands-on approach to guiding portfolio companies through their growth stages. The firm has a significant presence in Europe, with a focus on regions such as the Benelux, France, and Germany, aiming to build a new generation of leading biotech companies.

Bioverge is a venture capital firm and investment platform specializing in early-stage healthcare startups. Based in San Francisco, Bioverge provides accredited investors with opportunities to invest in innovative healthcare companies that aim to transform the industry. The platform leverages deep domain expertise and a robust network to offer exclusive access to premier healthcare startups, ensuring that investments have both high impact and the potential for significant returns. Bioverge Funds, such as the Bioverge Access Fund, allow investors to diversify their portfolios by investing in a curated selection of healthcare startups through a single investment. These funds provide preferred access to deals, discounted fees, and the benefit of spreading investment risk across multiple companies. Bioverge emphasizes a data-driven investment approach, utilizing AI to select the most promising opportunities in the healthcare sector. Notable investments by Bioverge include companies like Enveda, which focuses on developing next-generation small-molecule therapeutics, and JelikaLite, which has created a non-invasive therapy for children with autism. Bioverge's investment strategy aims to support startups that offer groundbreaking solutions in healthcare, biotechnology, and medical technology. The firm was founded by Neil Littman, who brings extensive experience in healthcare venture capital. Bioverge's mission is to democratize access to high-quality healthcare investments, providing individual investors with the same opportunities as institutional investors.

Bits x Bites is a Shanghai-based venture capital firm and China’s first dedicated agrifood tech investor. Founded in 2016 by Matilda Ho, the firm focuses on early-stage startups tackling the most critical challenges in the food system, including food security, safety, and sustainability. Their investments span the entire food supply chain, from farm innovations to novel food production technologies, helping to revolutionize agriculture in China and beyond. Bits x Bites manages over $100 million across its funds, with a strong emphasis on scalable technologies that can make a measurable impact on food production and environmental sustainability. Their portfolio includes companies like EAVision, which specializes in autonomous drones for complex farming terrains, and Mojia Bio, a biomanufacturing startup that produces eco-friendly nutrients for the food industry. These investments reflect the firm’s commitment to advancing solutions in precision agriculture, alternative proteins, and biomanufacturing. With a global outlook, Bits x Bites evaluates around 1,200 startups annually, targeting companies with technologies that can be applied in China. They support their portfolio companies through partnerships with industry leaders such as Syngenta and Temasek, offering access to valuable resources and markets. The firm’s multidisciplinary team of experts provides hands-on guidance to help startups scale and commercialize their innovations in the Chinese market, shaping the future of food technology in the region​.

Black Bay Energy Capital is a New Orleans-based private equity firm that specializes in the energy sector, targeting North American companies. Established in 2016, it focuses on oilfield services, specialty chemicals, and midstream infrastructure, with an emphasis on solutions that reduce costs and improve operational efficiency. Black Bay is known for backing innovative companies like Advanced Industrial Devices and Capture Energy. The firm typically invests up to $30 million, favoring businesses with strong management teams and defensible competitive advantages. The firm's investment strategy prioritizes partnerships with entrepreneurs and is characterized by a thematic approach, leveraging its deep sector expertise. They prefer to lead rounds and often take control positions in their investments, although they remain flexible. Black Bay seeks companies with under $25 million EBITDA, ensuring scalable growth through operational improvements rather than financial engineering. Led by key figures such as Michael LeBourgeois and Matt Schovee, Black Bay is highly selective, only investing in businesses where it can add strategic value. Its geographic focus is primarily in the U.S., and the team actively supports its portfolio companies through technological investments and infrastructure development.

Black Pearls VC is an early-stage venture capital firm based in Gdańsk, Poland, with a strategic focus on the Baltic Sea Region and Central Europe. They are particularly keen on deep tech startups developing unique, scalable technologies. The fund supports businesses from seed to Series A stages, with initial investments ranging from €100k to €1m and follow-on investments up to €3m. The firm has a sector-agnostic approach but has made significant strides in digital health, enterprise software, fintech, and deep tech. Notable portfolio companies include Nanoxo, a developer of non-toxic quantum dots for various industries; Xopero, specializing in data protection solutions; and Prosoma, which offers digital therapeutics for cancer patients​. Black Pearls VC's investment strategy emphasizes collaboration, often co-investing with other prominent funds. They focus on backing entrepreneurs with groundbreaking ideas and providing extensive support through their global network of advisors and partners. The team includes experts like Managing Partner Marcin P. Kowalik, who brings a wealth of experience in corporate finance and investment management. For startups looking to attract Black Pearls VC, it is essential to highlight the scalability and uniqueness of their technology. Approaching them through detailed pitches that align with their deep tech focus can significantly increase the chances of securing funding.

Blackhorn Ventures is an early-stage venture capital firm that focuses on investing in companies that drive industrial efficiency and environmental sustainability. The firm targets sectors such as energy, construction, supply chain logistics, and transportation. Some of the notable portfolio companies include Aperia, which develops tire inflation systems for trucks; Agorus, known for building custom homes quickly and precisely; and Electric Era, which creates advanced energy storage systems for EV charging stations. Blackhorn Ventures employs a capital-efficient approach, leveraging AI and digital solutions to modernize traditional industries and improve operational efficiency. The firm is deeply committed to decarbonizing industry sectors and aligning investments with environmental sustainability goals. The firm is led by experienced investors and operators who focus on creating value and engaging collaboratively with their portfolio companies and strategic partners to achieve both financial returns and impactful outcomes.

Blindspot Ventures is a seed-focused venture capital firm based in Boston, specializing in backing visionary founders who are reshaping industries through platform technologies and infrastructure innovation. The firm is known for partnering with bold, iconoclastic entrepreneurs who challenge the status quo and develop foundational technologies that drive industry evolution. Their portfolio includes cutting-edge companies like Form Energy, Mori, bloXroute, and Volta Labs, all of which are pioneers in fields ranging from renewable energy storage to advanced material science. Blindspot primarily invests in early-stage companies, with a typical check size of $500K to $3M. Their geographic focus is predominantly on the U.S., leveraging Boston’s rich history of innovation and proximity to top-tier academic institutions. Blindspot actively supports its portfolio companies, often taking board seats and offering strategic advice to foster long-term partnerships. Led by managing partners Ahmed Hentati and Hassan Dayekh, Blindspot is driven by a passion for addressing critical global challenges. Hentati, deeply ingrained in Boston’s startup ecosystem, focuses on identifying and backing groundbreaking founders, while Dayekh manages operations and co-leads the investment committee, bringing extensive experience from his background in banking and growth-stage venture capital.

Bling Capital is a venture capital firm specializing in seed-stage investments, founded by Ben Ling, who has a strong track record with 19 "unicorn" investments. The firm focuses on helping entrepreneurs achieve product-market fit and scale their businesses. Bling Capital has recently announced the closing of its third fund, raising $212 million, which includes a $109 million core seed fund and a $103 million opportunity fund to support companies as they grow. The firm's investment strategy targets sectors such as B2B software, consumer tech, digital health, fintech, and the future of work. Bling Capital typically invests around $1 million at the seed stage and provides extensive support through its Product Council, which comprises over 100 top product leaders from various industries. Notable companies in Bling Capital's portfolio include Lyft, Palantir, Lucidchart, Udemy, Gusto, and Instacart. The firm is dedicated to partnering with high-potential founders and supporting them through every stage of their journey.

Bloomberg Beta, an early-stage venture capital firm launched in 2013, manages $375 million in total across several funds. Backed solely by Bloomberg L.P., the firm focuses on investing in startups that aim to improve the future of work, emphasizing machine intelligence and data-centric technologies. Notable investments include companies such as Repl.it, a cloud computing platform for developers; LaunchDarkly, which helps software teams build better software faster; and StrongDM, an infrastructure access platform. Bloomberg Beta has also had significant exits, including Rigetti Computing, Orbital Insight, and Flashpoint​. The firm operates independently from Bloomberg L.P., and its team, led by Roy Bahat, Karin Klein, and James Cham, employs a unique investing model where any team member can independently approve deals. They maintain a strong commitment to transparency, with their operating manual and investment criteria publicly available on GitHub​​. Bloomberg Beta supports entrepreneurs through various stages of growth, leveraging data to identify potential founders and emphasizing a collaborative approach to investment. Their investment strategy is broad, focusing on startups that can bring transformative changes to how businesses operate and how people work

Blossom Capital, founded in 2017 and headquartered in London, has quickly established itself as a leading Series A investor in Europe. Led by Ophelia Brown, Imran Ghory, and Alex Lim, Blossom Capital focuses on high-potential sectors such as fintech, consumer internet, Web3, and enterprise SaaS. Notable investments include Moonpay, Checkout.com, Fat Llama, and Tines, demonstrating their knack for backing innovative startups. Blossom's strategy emphasizes deep, hands-on involvement, limiting investments to 5-6 Series A rounds per year to provide focused support. This approach includes assisting with recruitment, go-to-market strategies, and subsequent fundraising efforts. They prioritize building strong, long-term relationships with founders, often spending months getting to know them before committing to an investment​. The firm has a robust track record, with portfolio companies like Checkout.com and Moonpay achieving significant growth and valuations. Blossom's $432 million third fund, raised from prominent US and European investors, underscores their commitment to nurturing Europe's tech ecosystem​. For startups seeking to partner with Blossom, the key is demonstrating a clear vision and potential for substantial market impact. They value founders who are not only innovative but also resilient and prepared to scale efficiently. Blossom’s team, known for their rigorous support and strategic insight, is dedicated to propelling their portfolio companies to new heights.

Blue Bear Ventures (BBV) is a venture capital firm focused on deep tech innovations emerging from top research institutions, especially within the University of California system. Founded in 2017, BBV backs startups at the frontier of science and technology, particularly in areas like AI, synthetic biology, energy, and gene therapy. They work closely with founders who are often scientists and engineers, helping translate cutting-edge research into scalable businesses. The firm builds on its roots in the CITRIS Foundry accelerator at UC Berkeley, where it has nurtured groundbreaking startups. BBV typically invests in early-stage companies, emphasizing the impact of technology on sectors such as healthcare, energy infrastructure, and materials science. Some of their portfolio companies include Ayar Labs (optical data transmission), Clarity (air quality monitoring), and Coreshell (battery nanotechnology)​. BBV is committed to supporting deep tech entrepreneurs through a combination of financial investment and hands-on guidance, fostering startups that aim to solve global challenges.

Blue Horizon is a Zurich-based venture capital firm focused on investing in the future of food. Founded in 2016 by Bjoern Witte and Roger Lienhard, the firm has established itself as a leader in the sustainable food sector, managing over $850 million in assets and investing in more than 60 companies globally. The firm primarily targets the alternative protein and food technology industries, with notable investments in companies like Impossible Foods, Mosa Meat, and Planted. These investments reflect Blue Horizon's commitment to pioneering innovations that promote sustainability and environmental responsibility. Mosa Meat, for instance, developed the world’s first lab-grown beef burger, while Planted is a notable player in the vegan meat market. Blue Horizon’s investment strategy emphasizes a full lifecycle approach, supporting companies from seed stage through to significant growth phases. They focus on businesses that offer transformative solutions to global challenges in the food system, such as reducing reliance on traditional meat and dairy production, and promoting plant-based and cultured food alternatives. For startups looking to connect with Blue Horizon, demonstrating a strong alignment with their mission of creating a sustainable food system and showcasing innovative solutions that address significant market opportunities are key to forming a successful partnership.

Blue Ocean Partners, managed by SWEN Capital Partners, is a pioneering venture capital firm dedicated to restoring ocean health through impactful investments. Launched in 2021, Blue Ocean has quickly become the world’s largest ocean-focused venture fund, closing at €170 million in 2023, far exceeding its initial target of €120 million. The fund targets startups that are developing innovative solutions to combat key challenges facing the oceans, including overfishing, pollution, and climate change. The fund’s portfolio includes a diverse range of companies that are driving significant environmental impact. For example, ECOsubsea offers environmentally friendly in-water hull cleaning services that reduce carbon emissions and prevent the spread of invasive species. Another portfolio company, BlueNav, develops hybrid electric propulsion systems that help reduce the carbon footprint of marine transportation. Additionally, Avant is pioneering the production of cultivated seafood, offering a sustainable alternative to traditional fishing practices. Blue Ocean Partners is committed to generating both financial returns and measurable environmental outcomes. The fund’s investments are aligned with global efforts to regenerate marine ecosystems and contribute to the broader movement of sustainable ocean innovation. As a co-founder of the 1000 Ocean Start-ups initiative, Blue Ocean Partners plays a key role in scaling transformative ocean-focused technologies globally, further solidifying its leadership in the ocean impact investing space.

Blue Wire Capital, established in 2013, is a London-based venture capital firm that focuses on early-stage investments, particularly in the pre-seed and seed stages. The firm invests across industries such as business software, environmental services, and educational technology. Notable portfolio companies include Climate X, Five, and Praktika.ai. Geographically, their investments are concentrated in Europe, with a strong presence in London. Blue Wire Capital's strategy emphasizes supporting visionary entrepreneurs addressing global challenges through technology. They typically lead investment rounds, with average check sizes around $5.96 million. They are active, engaging in 2-6 deals annually, and maintain a flexible approach to capital deployment. The team includes Bertie Highmore, Head of Investments, who brings experience from Goldman Sachs and Susquehanna International Group. To approach Blue Wire Capital, startups are advised to demonstrate innovative solutions with significant impact potential. The firm values fast and flexible access to capital, providing not just funding but also strategic support and networking opportunities to foster entrepreneurial success.

BlueRun Ventures (BRV), founded in 1998 and headquartered in Menlo Park, CA, is an early-stage venture capital firm with a global presence. The firm has offices in the United States, China (Beijing and Shanghai), and South Korea. BRV is known for its focus on mobile, fintech, digital health, and consumer experiences, targeting startups that solve significant problems in these sectors. BRV's portfolio boasts notable investments including PayPal, Waze, Coupa, and Kabbage, showcasing their track record in identifying and nurturing high-potential companies. The firm’s investment strategy involves leading seed and Series A rounds, typically investing between $2 million and $8 million per deal. They prioritize early-stage companies that exhibit strong growth potential and innovative solutions. The BRV team consists of experienced professionals such as co-founders John Malloy and Jonathan Ebinger, who bring deep expertise in mobile software, services, and financial technology. The team leverages its collective experience in product development, marketing, and design to support portfolio companies. Startups looking to engage with BRV should emphasize their potential for disruption and scalability. The firm values entrepreneurs who are pushing industry boundaries and can benefit from BRV’s extensive network and hands-on approach to growth.

BlueYard Capital is a venture capital firm that invests in early-stage companies with transformative potential across various industries. Established to support innovative founders, BlueYard focuses on creating a future where markets are open and decentralized, significant planetary challenges are addressed, and knowledge and data are liberated. The firm is known for its thematic investments in sectors like blockchain, crypto, artificial intelligence, web3, and biotechnology. BlueYard has a diverse portfolio that includes companies such as Bit Bio, Meatable, and Biofidelity, which are involved in biotechnology and healthcare innovations. The firm also invests in blockchain and crypto platforms like Centrifuge and Agnostic, aiming to revolutionize data management and financial systems. The firm's investment strategy emphasizes backing open-ended, breakthrough research and early-stage startups. BlueYard's portfolio companies benefit from its extensive network, strategic guidance, and a supportive investment environment that fosters innovation and growth.

Blumberg Capital is an early-stage venture capital firm that invests in startups from inception through growth stages. With over $650 million in assets under management, the firm focuses on sectors such as fintech, AI, cybersecurity, enterprise software, and digital health. Blumberg Capital has been a key player in supporting companies that use transformative technologies to empower individuals and businesses. Notable investments include Nutanix, BioCatch, and DoubleVerify, demonstrating their success in various tech-driven industries. Additionally, Blumberg Capital has heavily invested in fintech companies, making up about 29% of their portfolio. Key fintech investments include Fundbox, Lendio, and Addepar. The firm is known for its hands-on approach, providing not just capital but also strategic support, leveraging its extensive network and expertise to help startups succeed. Blumberg Capital's investment strategy involves leading seed and Series A rounds, with initial investments ranging from $500,000 to $5 million. They are committed to partnering with visionary entrepreneurs and helping them navigate the challenges of scaling their businesses. The firm operates internationally, with offices in Miami, New York, San Francisco, and Tel Aviv. Their approach and successful track record make Blumberg Capital a prominent player in the venture capital landscape, supporting innovative companies that are shaping the future through technology​.

bmp Ventures is a seasoned venture capital firm based in Berlin, Germany, with over 25 years of experience in early-stage and growth investments. Since its founding in 1997, bmp Ventures has managed 11 venture capital funds and made more than 250 investments, resulting in over 120 exits and more than 20 IPOs. The firm focuses on investing in innovative and scalable companies across various sectors, including digital solutions, industry & deeptech, media & gaming, life sciences & eHealth, cleantech & planet positive, mobility & automotive, and fintech & legaltech​. They typically invest between €350,000 to €3 million in seed and early-stage rounds, with the potential to invest up to €10 million per company through subsequent financing rounds. bmp Ventures is known for being a hands-on investor, providing extensive support to their portfolio companies. This includes strategic advice, networking opportunities, assistance with business model refinement, and guidance on fundraising and exit strategies​.

Boehringer Ingelheim Venture Fund (BIVF) is a dynamic venture capital arm of Boehringer Ingelheim, investing in groundbreaking biotechnologies and therapeutics. BIVF's notable portfolio includes companies like HepaRegenix, focusing on liver regeneration; Imcheck Therapeutics, developing novel cancer immunotherapies; and Asgard Therapeutics, pioneering gene therapy-mediated cancer treatments. BIVF primarily targets biotech startups in areas such as oncology, regenerative medicine, infectious diseases, and digital health, with a strong emphasis on early-stage investments. They invest globally, with significant activity in Europe, the US, and Asia, aiming to foster innovation that aligns with Boehringer Ingelheim's strategic interests. Their strategy involves taking minority stakes and actively supporting companies through the pre-seed, seed, and series A stages. BIVF typically leads funding rounds, providing crucial support in both capital and expertise. They prefer startups that are exploring novel therapeutic approaches with the potential for significant clinical impact. For startups looking to engage with BIVF, it’s essential to have a groundbreaking technology with strong preclinical or early clinical data. They value strategic alignment with Boehringer Ingelheim’s therapeutic areas and appreciate a collaborative approach from entrepreneurs.

Boğaziçi Ventures, established in 2015 and headquartered in Istanbul, Turkey, is a venture capital firm focusing on early-stage investments in technology-driven sectors. They target industries such as fintech, health tech, retail tech, and gaming, aiming to support innovative startups that can achieve substantial growth and impact. Notable investments by Boğaziçi Ventures include Cerebrum Tech, a company specializing in digital transformation solutions, and Hiwell, an online therapy platform. They have made 59 investments, primarily within Turkey, but also in regions like the United Kingdom and the United States. The firm is led by co-founders Barış Özistek and Burak Balık, who, along with their team, emphasize sustainable development goals in their investment strategies. Boğaziçi Ventures supports its portfolio companies with not only financial backing but also strategic guidance to help them scale effectively.

Bold Capital Partners is a venture capital firm based in Santa Monica, California, with an additional office in Boston, Massachusetts. Founded in 2015 by Peter Diamandis, the firm focuses on investing in groundbreaking technologies and innovative companies that aim to solve humanity's biggest challenges. Their investment strategy targets sectors including advanced robotics, AI, healthcare, and sustainable technologies. Notable portfolio companies include Rugged Robotics, which provides automated construction solutions, and Mighty Buildings, which focuses on sustainable 3D printing for construction. Bold Capital Partners supports startups at various stages, from seed funding to growth stages, emphasizing disruptive potential and significant market impact. The team at Bold Capital Partners includes experienced professionals such as Managing Partner Teymour Boutros-Ghali, General Partner Emilio Diez Barroso, and Operating Partner Helen McBride, who bring a diverse range of expertise in investment and entrepreneurship. They leverage their extensive network and industry knowledge to provide strategic support to their portfolio companies. Bold Capital Partners is committed to uplifting humanity through strategic investments in technologies that democratize and transform major markets​.

Bolt is a pre-seed venture capital firm that invests in startups operating at the intersection of the digital and physical worlds. Founded in 2012, Bolt focuses on companies leveraging innovative technologies and valuable data sets to reimagine products, systems, and experiences. The firm is known for leading the first round of financing in over 90% of its investments, which often include unique hardware and software combinations​. Bolt's portfolio includes notable companies like Tonal, Desktop Metal, Pair Eyewear, and Tive. These companies span various sectors, showcasing Bolt’s commitment to supporting a diverse range of innovative startups​​. The firm operates from Boston, Massachusetts, and is led by experienced partners such as Axel Bichara, Greg McAdoo, Kate McAndrew, Matt Thoms, and Tyler Mincey, all of whom bring extensive backgrounds in venture capital and entrepreneurship. Bolt also engages with the startup community through initiatives like Women in Hardware, a community supporting women and non-binary individuals in hardware development, and Groundwork, a workshop series for direct-to-consumer (DTC) founders.

Brabantse Ontwikkelings Maatschappij (BOM), based in Tilburg, Netherlands, is a venture capital firm dedicated to fostering innovation and economic growth in the Brabant region. Since its founding in 1983, BOM has been actively investing in startups and scale-ups across various sectors including renewable energy, high-tech systems, agro-food, life sciences, and med-tech. BOM has built a significant portfolio with notable investments in companies like Sirius Medical Systems, which enhances cancer treatment with precise surgical solutions, and AvL Motion, known for developing a robotic asparagus harvester. Another key investment is in LionVolt, which focuses on developing sustainable 3D solid-state batteries. BOM is recognized as the most active venture capital investor in Dutch startups, highlighting its commitment to driving economic impact and innovation in the region. Their strategic approach includes providing financial support and expertise to startups, ensuring these companies can grow effectively and sustainably. This proactive involvement has led to successful exits and significant contributions to societal transitions such as climate-neutral energy solutions and advancements in health technology. With a focus on creating a robust entrepreneurial ecosystem, BOM continues to support and invest in companies that have the potential to make substantial contributions to the Brabant economy and beyond.

BOND Capital is a global technology investment firm that focuses on supporting visionary founders throughout their entire innovation and growth lifecycle. Established in 2019, BOND is a spinout of the Kleiner Perkins Digital Growth Fund and was founded by Mary Meeker, along with other key partners. The firm invests in high-growth internet companies, emphasizing long-term partnerships with entrepreneurs who are transforming their industries. Notable investments include prominent companies like Stripe, Canva, and Airbnb. BOND Capital aims to leverage its extensive network and expertise to provide strategic guidance and resources to its portfolio companies. Based in San Francisco, BOND operates with a global outlook, seeking opportunities in diverse markets to support groundbreaking technological advancements​.

Boom Capital, founded in 2016 by Celestine “Cee Cee” Schnugg, is a San Francisco-based venture fund focused on early-stage investments in cutting-edge scientific fields. The firm specializes in deep tech sectors, including healthcare, genomics, machine intelligence, aerospace, and innovative chemistry. Boom Capital's unique value proposition is its deep integration into the scientific community, giving it first access to groundbreaking companies born from frontier science. Leveraging a network of top-tier scientists, including Nobel Prize winners, the firm is positioned to partner with founders long before their ideas are widely recognized. Boom Capital has a track record of identifying transformative technologies early and providing significant support in terms of capital and mentorship. Its portfolio boasts notable companies such as Mammoth Biosciences, Diligent Robotics, Fauna Bio, and A-Alpha Bio, all leaders in their respective fields. The firm has also seen several successful exits, including Planet Labs and Swarm Technologies—the latter being acquired by SpaceX. With a focus on accelerating the journey from research to commercialization, Boom Capital is committed to nurturing the “scientist-protagonists” who are pushing the boundaries of innovation. Its mission is to support high-impact founders with transformative potential, often before traditional investors take notice. By offering not only capital but also access to a vast network of scientific and technical expertise, Boom Capital plays a crucial role in turning visionary ideas into successful ventures.

Boost VC, founded by Adam Draper and Brayton Williams in 2012, is a venture capital firm based in San Mateo, California, that focuses on early-stage investments in frontier technologies. With over $200 million in assets under management, Boost VC typically invests $500,000 in pre-seed startups, supporting over 300 companies. Their portfolio includes notable companies like Coinbase, Protocol Labs, and Snapcard, and spans deep tech sectors such as crypto, VR, AR, AI, space tech, robotics, and bio/health. Boost VC operates a rigorous accelerator program, providing startups with mentorship, resources, and networking opportunities. The three-month program offers intensive support from the Boost VC team and access to a wide network of industry experts and investors. The firm is known for its strong commitment to fostering innovation and diversity within the tech industry, actively supporting women and underrepresented founders. Adam Draper, a fourth-generation venture capitalist, and Brayton Williams, bring extensive experience and a vision for transformative technology startups. The team includes partners like Maddie Callander and Gus Domel, who offer diverse expertise from private aviation to brain health technology.

Borski Fund is a pioneering venture capital firm based in Amsterdam that focuses on closing the gender gap in venture capital by investing in companies led by women or gender-diverse teams. Founded in 2019 by Simone Brummelhuis and Laura Rooseboom, Borski Fund is named after Johanna Borski, a 19th-century Dutch financier who was instrumental in funding the Dutch Central Bank. The fund is dedicated to supporting female entrepreneurs and teams with at least one female executive with equity stakes, aiming to foster innovation, inclusivity, and economic growth. Borski Fund’s investment thesis is centered around the belief that diversity leads to better decision-making and stronger business outcomes. The fund’s portfolio includes companies across various sectors, including technology and sustainability, with a particular focus on those driven by data and AI. Borski Fund also stands out due to its collaboration with major partners like the Visa Foundation, which recently contributed to expanding the fund to €40 million. This partnership reflects a shared commitment to promoting gender equality in the startup ecosystem, and the fund has made significant strides in empowering women-led businesses across Europe. By creating opportunities for women and gender-diverse teams, Borski Fund is not only addressing the significant investment gap in venture capital but also championing a more equitable and inclusive business environment.

Bossanova Investimentos, often referred to as Bossanova Invest, is a prominent venture capital firm based in Brazil, specializing in pre-seed stage investments. Founded in 2011 by Pierre Schurmann and later joined by João Kepler, Bossanova has established itself as the most active micro-VC in Latin America. The firm focuses on B2B and B2B2C technology companies that are innovative, digital, and scalable​​. Bossanova has invested in over 1,200 startups across more than 1,000 companies, making it a significant player in the early-stage investment scene. Their portfolio includes notable exits such as Glovo, Upsie, and Shift​​. They employ a rigorous selection process and offer extensive support to their portfolio companies to ensure rapid growth and success. The firm's investment strategy revolves around startups that are over 1.5 years old, have found a problem-solution fit, and are already operational and generating revenue. They avoid investments in sectors that exclusively target government, e-commerce, games, or hardware that competes with existing portfolio companies​. Bossanova's network includes over 10,000 co-investors, founders, and partner companies, providing a robust ecosystem for startups to thrive. They also offer educational resources through platforms like Clubb.vc, which provides courses and materials on investment, innovation, and business development​​. In addition to traditional equity investments, Bossanova has introduced an innovative investment model via Cédula de Crédito Bancário (CCB), which allows investors to gain exposure to the startup ecosystem with capital protection and fixed returns​​. This approach aims to democratize access to venture capital investments, making it accessible to a broader range of investors.

Boulder Ventures, established in 1995, is a venture capital firm that focuses on investing in early-stage information technology and life sciences companies. With headquarters in Boulder, Colorado, and an office in the Mid-Atlantic region, the firm leverages decades-long relationships with entrepreneurs and investors to drive its investment strategy. Boulder Ventures has raised eight funds totaling approximately $429 million, with the most recent fund, Boulder Ventures VIII, closing at $58 million in 2022. The firm has a notable track record, having invested in 61 companies, leading to 28 exits and 10 IPOs​. Key investments by Boulder Ventures include companies like Array BioPharma (acquired by Pfizer for $11.8 billion), LeftHand Networks (acquired by HP), and Wall Street on Demand (acquired by Goldman Sachs). The firm’s portfolio is diverse, covering sectors such as software, IT services, storage and communications, and life sciences. Kyle Lefkoff, the founder and general partner, brings over 38 years of venture capital experience. His extensive background includes significant roles in guiding companies through critical growth stages and strategic exits​.

Boundary Capital is a London-based venture capital firm focused on impact investing in early-stage companies that aim to improve lives and deliver strong commercial returns. Their investment strategy centers on technologies in life sciences, engineering, and data science that address critical global challenges such as healthcare, sustainability, and education. By aligning economic success with positive societal impact, Boundary Capital looks for businesses that offer innovative solutions to real-world problems. The firm typically invests in businesses from late seed to Series B stages, targeting returns of 3x within five to seven years. They place a strong emphasis on companies with proven economic potential and intellectual property advantages. Their portfolio includes high-growth companies like Glyconics, which is developing diagnostics for chronic lung diseases, and Echion, which focuses on fast-charging battery technology. Boundary's team combines extensive entrepreneurial and investment expertise. Led by Managing Partner Dan Somers, the firm supports portfolio companies with strategic guidance, leveraging both their financial investment and hands-on operational support.

Bow Capital, established in 2016 and based in Menlo Park, California, is a venture capital firm that leverages its strong connection with the University of California system to access a rich ecosystem of academic and research resources. This partnership provides them with broad access to the UC's 2.6 million faculty, staff, students, and alumni, as well as numerous research centers and medical facilities​. Bow Capital invests primarily in early-stage startups, focusing on sectors such as artificial intelligence, machine learning, big data, and enterprise software. Their portfolio includes notable companies like Ambi Robotics, Heartex, and Linus Biotechnology. The firm aims to bridge the gap between academia and industry, helping to commercialize innovative technologies and scientific discoveries. The investment strategy at Bow Capital includes participating in pre-seed, seed, and Series A funding rounds. They emphasize not only financial support but also strategic guidance and operational expertise, leveraging their network of Silicon Valley founders and industry leaders to help startups grow and succeed​. Notable exits for Bow Capital include companies like RealtyShares, Rimeto, and Skylight, reflecting their ability to identify and nurture high-potential startups to successful outcomes.

BoxGroup is a prominent early-stage venture capital firm based in New York City, established in 2009 by David Tisch and Adam Rothenberg. The firm focuses on investing in pre-seed to Series A rounds, targeting sectors such as consumer technology, enterprise software, fintech, healthcare, life sciences, and marketplaces. BoxGroup has built a robust portfolio with notable investments in companies like Plaid, Airtable, Ro, Ramp, Warby Parker, and Harry’s. They are known for their early-stage support and have made over 600 investments, actively backing innovative startups with the potential to disrupt and define new market categories. BoxGroup typically invests between $50,000 to $250,000 per deal, emphasizing conviction in the founding teams they support. Their approach is geography-agnostic, although they have a strong presence in key tech hubs such as New York, Silicon Valley, and Los Angeles. The firm has also seen several successful exits, including high-profile IPOs and acquisitions. They aim to be one of the earliest and most supportive investors, providing strategic guidance and leveraging their extensive network to help startups grow and succeed.

BoxOne Ventures, established in 2018 and based in Montreal, Canada, is a venture capital firm that focuses on early-stage investments across diverse and impactful sectors. The firm invests in companies with strong technology platforms in areas such as biotechnology, computational biology, AI and data analytics, digital health, fintech, and food technology. BoxOne Ventures has built a robust portfolio featuring notable investments like Juvena Therapeutics, which raised $41M to advance therapeutic solutions. Other significant investments include companies like dfuse, a blockchain development platform, and Odd Burger, a plant-based fast food chain. The firm’s strategy includes backing talented entrepreneurs and innovative technologies that aim to make a positive difference globally. The team at BoxOne Ventures comprises experienced founders and investors who are deeply involved in the development and support of their portfolio companies. This hands-on approach helps startups navigate the challenges of scaling and achieving market success.

New Science Ventures (NSV), founded in 2004, is a venture capital firm that focuses on investments in life sciences and information technology. With offices in New York and London, NSV aims to leverage breakthrough science to create significant value. The firm has a diverse portfolio, investing in companies that utilize fundamental, science-based innovations to address large unmet needs. NSV's notable investments include Ventyx Biosciences, which raised $114 million to advance its pipeline of immunology programs, and Paragraf, a company that mass-produces graphene electronics. Other significant portfolio companies are Phase Four, which develops next-generation electric propulsion solutions for satellites, and NorthSea Therapeutics, which focuses on novel treatments for liver-related diseases​. The firm typically invests in early to mid-stage companies and supports them through crucial value inflection points to help them scale. Their investment strategy is grounded in strong intellectual property protection and a long-term view​.

Braemar Energy Ventures, founded in 2002, is a New York-based venture capital firm with a strong focus on energy technology and innovation. Notable investments include ChargePoint, Getaround, and Metalenz, showcasing their dedication to transformative energy and tech sectors. They are particularly interested in energy technology, mobility, power, and infrastructure, with a geographic focus primarily on the United States. Braemar's investment strategy revolves around early to mid-stage funding, often leading rounds with substantial check sizes, as seen in Getaround’s $140 million Series E. The firm prides itself on being an active investor, often leading investments and working closely with entrepreneurs to navigate the complexities of the energy transition. Key team members include co-founders William Lese and Neil Suslak, who bring extensive experience and industry connections. Braemar Energy Ventures has a robust track record, with 19 exits including prominent companies like ChargePoint and Viridity Energy. They are approachable for startups looking for engaged and knowledgeable partners in the energy sector, typically through direct networking and industry events. Braemar's team, based mainly in New York, leverages their deep industry expertise to identify and support promising ventures, aiming to drive significant environmental and societal impact through their investments. For startups, aligning with Braemar’s focus on innovation and sustainability in energy technology is key to capturing their interest and securing funding.

Bread and Butter Ventures, based in Minneapolis, Minnesota, is an early-stage venture capital firm that invests globally while leveraging the region's strong corporate connections and industry expertise. Founded in 2017, the firm focuses on several key sectors including health tech, food tech, and enterprise SaaS. Their portfolio includes notable investments such as Ducky, an automation and workflow software company; Chiyo, which focuses on food and agriculture technology; SocialCrowd, a platform for enterprise applications; and Nest Collaborative, a health tech company providing virtual lactation support. They have made a total of 87 investments, emphasizing their active involvement in the startup ecosystem. Bread and Butter Ventures has also seen successful exits, including Upsie, a technology company that was acquired, and Spoonshot, which was also successfully exited. The firm is led by Managing Partners Brett Brohl and Mary Grove, who bring extensive experience in technology and early-stage investing.

Break Off Capital is a forward-looking venture capital firm that focuses on funding early-stage companies at the cutting edge of technology. With a mission to "fund the future," the firm actively seeks out innovative projects that have the potential to disrupt traditional industries and drive significant technological advancements. Their investment strategy centers on emerging sectors such as quantum computing, artificial intelligence, and other transformative tech domains that promise to reshape the way industries operate. The fund typically supports ventures in their formative stages, providing not only capital but also strategic insights to help startups scale and navigate competitive landscapes. Break Off Capital emphasizes long-term partnerships, working closely with entrepreneurs to refine business models, accelerate product development, and access broader markets. By leveraging their vast network, they help connect portfolio companies with essential resources, strategic partners, and additional investors. The team at Break Off Capital consists of seasoned professionals with diverse backgrounds in finance, technology, and strategic consulting. Key figures include senior adviser Ian, who brings extensive experience from his time at Eastdil, where he co-founded the Hong Kong office and honed his expertise in global capital markets. The team’s collective experience and strategic acumen enable them to identify high-potential ventures and provide the necessary support to turn visionary ideas into reality. Through a blend of capital investment, strategic mentorship, and industry connections, Break Off Capital is committed to backing ventures that are poised to lead the future of technology and innovation​.

Break Trail Ventures is an early-stage venture capital firm based in Columbus, Ohio, and Boulder, Colorado. Founded in 2018, the firm focuses on investing in startups that are innovating in sectors such as consumer products, advanced manufacturing, big data, digital health, e-commerce, mobile, SaaS, and the Internet of Things. The firm has built a diverse portfolio that includes notable companies like Cotopaxi, an outdoor gear brand committed to sustainability; Oiselle, a women's athletic apparel company; and Pepper, a lingerie brand designed for smaller cup sizes. Break Trail Ventures aims to support entrepreneurs who are pioneering new paths in their industries, emphasizing a customer-first approach and solving significant problems. Break Trail Ventures operates with a mission to partner closely with founders, providing not only capital but also strategic guidance to help startups achieve product-market fit and scale effectively. The firm is led by Managing Partner Jay Hirsh, who brings extensive experience in venture capital and entrepreneurship..

Breakout Labs, founded in 2012 as part of the Thiel Foundation, is an incubator and venture fund that supports early-stage, deep science companies with radical and emerging technologies. The fund provides up to $350,000 in initial funding and extensive support for startups that are too speculative for traditional venture capitalists. Breakout Labs focuses on companies at the intersection of technology, biology, materials, and energy, aiming to transition groundbreaking scientific discoveries from the lab to the market​. Notable portfolio companies include SciBac, which targets antibiotic-resistant diseases through microbiome science, and Azitra, which leverages the skin’s microbiome to treat skin diseases. Other innovative investments include ZymoChem, which develops sustainable chemical production processes, and EpiBone, which grows custom bones using 3D imaging and stem cells​. Breakout Labs has a history of significant follow-on funding for its portfolio companies, totaling over $1 billion. This success underscores their commitment to supporting the entire lifecycle of their investments, from seed to scale. The team, led by Managing Partners Lindy Fishburne and Julia Moore, includes experts who provide strategic guidance and leverage a vast network of founders, corporate partners, and advisors.

Breakout Ventures is a San Francisco-based venture capital firm founded in 2016, focused on early-stage investments in creative bioscience companies. The firm is dedicated to supporting startups that leverage the convergence of biology, chemistry, and technology to develop bio-based solutions aimed at improving human health and sustainability​. Breakout Ventures has raised significant capital, including a $112.5 million Fund II, to back innovative companies at the intersection of technology and biology. Their investment portfolio includes companies like Immusoft, which is working on genetically modifying B cells for sustained therapeutics, and Checkerspot, which uses synthetic biology to produce bio-derived oils​. The firm's investment strategy targets areas such as synthetic biology, cell and gene therapy, biomanufacturing, and carbon transformation, supporting companies from seed to scale. Notable portfolio companies include Cytovale, which focuses on diagnosing immune-mediated diseases, and Ecovative Design, which uses mycelium technology for sustainable materials. The Breakout Ventures team, led by managing partners Lindy Fishburne and Julia Moore, brings extensive experience in supporting science-driven companies. The firm originated from Breakout Labs at the Thiel Foundation, which has a strong history of advancing early-stage deep science startups​.